Cargando…
Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of survivin studies in the cancer field. Many studies have provided intriguing insight into surviv...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704566/ https://www.ncbi.nlm.nih.gov/pubmed/31439015 http://dx.doi.org/10.1186/s13046-019-1362-1 |